Obesity is a body condition in which a person’s weight is above the normal range. It’s an illness that can lead to a slew of additional issues. Obesity is when people consume more calories than their body demands—these extra sets of calories are stored as body fat. The amount of body fat you retain and where that fat is distributed may be influenced by the genes you receive from your parents. However, long-term sustainable weight loss cases have recently increased if the doctor collaborates with a team of professionals, such as psychologists, nutritionists, and exercise specialists.
As per the findings of the World Health Organization, the world has more than 2 billion overweight adults living in different regions, and out of the 650 million are categorized as obese. Although there are genetic, behavioral, metabolic, and hormonal influences on body weight, obesity generally develops when one takes more calories than the actual requirement for the body. In the world’s developed regions, a large section of the population has a high-calorie intake due to the consumption of high-calorie beverages and fast food.
Report Key Takeaways
Recommended Prevention and Treatment Options for Obesity:
Liraglutide is among the commonly used medication to treat diabetes. Liraglutide, unlike other weight-loss drugs, is administered through injection. Nausea is a very common ailment. Therefore, its use may be limited if you vomit.
Phentermine-topiramate is a weight-loss medication that also acts as an anticonvulsant. Heart rate and blood pressure increase, sleeplessness, constipation, and nervousness are all possible side effects.
Orlistat can be accessed without needing a prescription, but if it is in a reduced-strength variant. Loose stools and flatulence are adverse effects that are associated with the Orlistat. In addition, Orlistat has been linked to a small number of significant liver injuries.
Recent Developments Related to Obesity
- At the 82nd annual scientific sessions of the American Diabetes Association, Zealand Pharma officially published the reports from the Dapiglutide Phase 1 Trial on June 6, 2022. After this presentation, the company announced that Dapiglutide would be tested in the Phase 2 Obesity Trial.
- Tirzepatide was licensed by the US Food and Drug Administration in May to treat Type 2 diabetes. The experimental drug developed by the US Pharma Company, Eli Lilly, has also been hailed as an alternative to bariatric surgery. According to a study, using a medicine once a week can result in significant and long-term weight loss.
Major Players Working on Obesity
Leading companies such as Allysta Pharmaceuticals, Pfizer, Novo Nordisk, Vivus Pharmaceuticals, Empros Pharma, Boehringer Ingelheim, Lobesity Pharma, and GlaxoSmithKline are working rigorously to provide effective obesity management solutions. The FDA has approved Eli Lilly’s diabetic medicine Mounjaro. This first-of-its-kind treatment can help patients control their blood sugar while potentially assisting them in losing weight.
Key Reasons to Purchase This Report
- The pipeline insight features an in-depth global outlook of the modern therapies under different development phases and future potential for working on the obesity pipeline.
- A broader overview of leading companies involved in developing advanced drugs/treatment solutions and their recent activities in the pipeline domain.
A comparative analysis of different obesity products under clinical and non-clinical phases, along with an assessment of potential risks and prevailing opportunities in the pipeline landscape.